Spots Global Cancer Trial Database for HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

Official Title: Evaluation of HER2 Mutations in Patient Tumors From E2598

Study ID: NCT00896909

Conditions

Lung Cancer

Interventions

gene expression analysis

mutation analysis

polymerase chain reaction

diagnostic laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: Collecting samples of tumor tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at HER-2 mutations in tumor samples from patients with advanced non-small cell lung cancer being treated with trastuzumab on clinical trial ECOG-2598.

Detailed Description: OBJECTIVES: * Correlate clinical response to trastuzumab (Herceptin®) with the presence of mutation in the HER-2 kinase domain in tumor samples from patients with advanced non-small cell lung cancer treated on protocol ECOG-2598. * Correlate mutations with time to progression and survival of these patients. OUTLINE: This is a multicenter study. Tissue specimens are analyzed by polymerase chain reaction to assess mutations in the HER-2 gene. Laboratory/biomarker analysis data is correlated with clinical data from protocol ECOG-2598. PROJECTED ACCRUAL: A total of 22-44 patients will be accrued for this study.